TheraRadar
← Back
Data updated: Nov 8, 2026

AQUESTIVE

Pharma
Neurology Execution: Good

AQUESTIVE is a pharmaceutical company focused on Neurology. Key products include EXSERVAN.

2010
Since
3
Drugs
-
Trials
0
New Drugs (2yr)

AQUESTIVE at a Glance

  • Fast trial execution (14 months median completion)

Upcoming FDA Decisions

Full Calendar →
Mar 16, 2027 — Resubmission

AQUESTIVE's Key Drugs

AQUESTIVE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

AQUESTIVE's Recent FDA Approvals

New NDA/BLA approvals for AQUESTIVE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AQUESTIVE's Therapeutic Areas

AQUESTIVE's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
0 drugs Phase 3: 1 Phase 2: 2 Phase 1: 1

AQUESTIVE's Top Competitors

AQUESTIVE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Neurology
AbbVie big-pharma
Neurology
Eli Lilly big-pharma
Neurology
Roche big-pharma
Neurology
Bristol-Myers Squibb big-pharma
Neurology

AQUESTIVE Pipeline Snapshot

AQUESTIVE has 4 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 2 Phase 2 and 1 Phase 1.

1
Phase 3
2
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Neurology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 1/1 completed
  • • Speed: 14 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges